Skip to content
Screener

Accrued Expenses at other companies

Schrodinger logo
SchrodingerSDGR
$10.67M+3.9%
Recursion Pharmaceuticals, Inc. logo
Recursion Pharmaceuticals, Inc.RXRX
$17.96M-39.5%
Celcuity logo
CelcuityCELC
$1.25M-94.5%
Ligand Pharmaceuticals logo
Ligand PharmaceuticalsLGND
$4.64M+84.4%
Immunome logo
ImmunomeIMNM
$29.72M+63.1%
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
$1.42M-79.3%

Other financials

Income statement

See full
Revenue$350.0K-48.3%
Operating income-$90.8M-18.2%
Net income-$83.7M-18.9%
EPS (diluted)-$0.410.0%

Balance sheet

See full
Cash & equivalents$121.2M+6.4%
Total debt$30.7M-10.3%
Total equity$890.0M+33.7%
Total assets$967.5M+32.7%

Cash flow

See full
Operating cash flow-$54.1M+2.1%
CapEx$1.0K
Free cash flow-$44.9M+22.5%

Valuation

See full
Market cap$4.37B+680%
Enterprise value$4.28B+790%
P/S422.2×+355×

Profitability

See full
Operating margin-2,999.4%-637pp
Net margin-2,763.6%-568pp
FCF margin-1,536%-429pp

Returns & leverage

See full
Return on equity-36.8%-6.3pp
Debt / equity0.0×
Current ratio18.3×-2.7×

Where this comes from

Reported directly by Relay Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OtherLiabilitiesCurrent.

The source filing: Relay Therapeutics, Inc.’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 4:15 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-338056
Line itemJune 30, 2026December 31, 2025
Accounts payable$11,459$7,705
Accrued expenses34,07913,645
Operating lease liabilities4,0143,765
Other current liabilities1,252463
Total current liabilities50,80425,578
Operating lease liabilities, net of current portion26,64428,693
Total liabilities77,44854,271
Commitments and contingencies (Note 9)

Item 1. Financial Statements.

FAQ

What is Relay Therapeutics, Inc.'s accrued expenses?
Relay Therapeutics, Inc. (RLAY) reported accrued expenses of $1.25M in Q2 2026.
How has Relay Therapeutics, Inc.'s accrued expenses changed year-over-year?
Relay Therapeutics, Inc.'s accrued expenses increased by 105.6% year-over-year, from $609K to $1.25M.
What is the long-term trend for Relay Therapeutics, Inc.'s accrued expenses?
Over 5 years (2020 to 2025), Relay Therapeutics, Inc.'s accrued expenses has grown at a -39.6% compound annual growth rate (CAGR), from $5.76M to $463K.
What does accrued expenses mean?
Expenses incurred but not yet paid or invoiced — interest accruals, tax accruals, warranty reserves, and other timing differences.

Ask your AI about Relay Therapeutics, Inc.'s accrued expenses.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude